Showing results (71-80 of 126) with videos related to

Sort By:
Pageof 13
Leukemia|October 7, 2021
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AMLMatthieu Duchmann, Orianne Wagner-Ballon, Thomas Boyer, et al.
Transplantation and Cellular Therapy|August 16, 2025
Comparison of Outcomes after UM171-Expanded Cord Blood and Six Conventional Donor Source Transplants: A Matched Analysis from the EBMT RegistrySandra Cohen, Myriam Labopin, Nadia Bambace, et al.
Cancer Research|June 8, 2021
Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic MelanomaMarwa Zerhouni, Anthony R Martin, Nathan Furstoss, et al.
Leukemia Research|April 18, 2024
Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemiaGuillaume Berton, Bochra Sedaki, Erwann Collomb, et al.
The Lancet. Haematology|May 28, 2023
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 studyPierre Peterlin, Yannick Le Bris, Pascal Turlure, et al.
American Journal of Hematology|October 27, 2020
Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide studyJean-Baptiste Bossard, Jean-Baptiste Beuscart, Marie Robin, et al.
Blood Neoplasia|June 2, 2025
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trialTimothy S Pardee, Bayard L Powell, Richard A Larson, et al.
Blood|October 15, 2016
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotypeAshley A Basiorka, Kathy L McGraw, Erika A Eksioglu, et al.
Blood Advances|February 11, 2021
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohortEdmond Chiche, Ramy Rahmé, Sarah Bertoli, et al.
Bone Marrow Transplantation|October 19, 2022
Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TCPaul Chauvet, Annalisa Paviglianiti, Myriam Labopin, et al.
Pageof 13